Development of topical microbicides that prevent sexual transmission of HIV is an active area of investigation. The purpose of this study was to test the ability of the potent membrane fusion inhibitor C34, an HIV gp41 antagonist, to block HIV infection of human Langerhans cells (LCs) in an epithelial environment that mimics a major route of HIV infection. We incubated freshly isolated epidermal explants containing LCs with various doses of C34 before, during, and after exposing explants to HIV. Although C34 only partially blocked HIV infection of LCs when pre-incubated with skin, it displayed full, dose-dependent inhibition when present during and after viral exposure. The poor protection from HIV infectivity in pre-incubated samples is consistent with mechanism of C34 inhibition and starkly contrasts to the full protection provided by PSC-RANTES, an entry inhibitor that prevents HIV gp120 interaction with its co-receptor CCR5. Real-time PCR confirmed that C34 blocked HIV infection of LCs before reverse transcription and inhibited LC-mediated transfer of virus to T cells. We conclude that C34, if used topically at susceptible mucosal sites, and if continually present, has the potential to block sexual transmission of HIV.
INTRODUCTION
HIV replication is a multi-step process that includes viral attachment to cell-surface receptors and co-receptors, fusion between virion envelope and cell membrane, reverse transcription, DNA integration, viral protein synthesis, and protease cleavage. Given the difficulty in developing an effective vaccine against HIV, researchers have expanded their focus on generating topical microbicides that could block sexual transmission of HIV at mucosal sites (Lederman et al., 2006) . Topical microbicides that are virucidal or that inhibit early steps in the HIV life cycle, such as viral attachment, fusion, and cell entry, are preferable to drugs that block late steps in the HIV life cycle, as they would block initial viral integration into chromosomal DNA. In this regard, we have previously shown that intravaginal topical use of N a -(n-nonanoy1)-des-Scr ] RANTES (PSC-RANTES) (regulated on activation normal T-cell expressed and secreted), an analogue of RANTES that binds the HIV co-receptor CCR5 and disrupts its interaction with the viral envelope glycoprotein Env, can completely block intravaginal infection of simian immunodeficiency virus in rhesus macaques (Lederman et al., 2004) . As the cost to produce PSC-RANTES is likely to be considerable, we have pursued additional drugs that block early steps of the HIV life cycle and that could serve as potential topical microbicides either alone or in combination with PSC-RANTES.
HIV gp41, the transmembrane subunit of Env, has recently emerged as a viable target for entry inhibition (Root and Steger, 2004) . Following the interaction of Env with cellular receptors, gp41 undergoes a series of coordinated structural changes, ultimately extending to insert its N-terminal fusion peptide into target cell membranes (Pierson and Doms, 2003) . Subsequently, the N-and C-terminal regions of the gp41 ectodomain associate to form a trimer-of-hairpins that juxtaposes the viral and cellular membranes in a manner required for efficient fusion (Chan et al., 1997; Weissenhorn et al., 1997; Melikyan et al., 2000; Markosyan et al., 2003) . Synthetic peptides derived from the C-terminal region of the gp41 ectodomain block trimer-of-hairpins formation, potently inhibiting viral entry (Jiang et al., 1993; Wild et al., 1994; Lu et al., 1995) . Denoted C-peptides, they bind the N-terminal region of the gp41 ectodomain exposed transiently in the extended intermediate conformation Furuta et al., 1998 ; Munoz-Barroso et al., 1998; Rimsky et al., 1998) . One C-peptide, T-20, demonstrates anti-viral activity in humans and has recently gained Food and Drug Administration approval for use to treat acquired immunodeficiency syndrome (Lalezari et al., 2003; Lazzarin et al., 2003) .
To test C-peptides as potential topical microbicides, we have developed and utilized an ex vivo skin explant model system (Kawamura et al., 2000 (Kawamura et al., , 2003 (Kawamura et al., , 2004 Ball et al., 2003; Sugaya et al., 2004) . This model utilizes suction blister roofs (i.e., epidermal sheets) to analyze the mechanism by which Langerhans cells (LCs) support initial HIV infection (Piguet and Blauvelt, 2002) . Although direct evidence of a dominant role for LCs in HIV transmission between humans is difficult to obtain, intraepithelial LCs have been shown to be the major cell type infected following non-traumatic intravaginal exposure to SIV in rhesus monkeys (Hu et al., 2000) . We have recently shown that pre-incubation of skin explants to drugs that disrupt HIV Env attachment to its receptors specifically blocks both the infection of LCs and their ability to transmit virions to T cells (Kawamura et al., 2003 (Kawamura et al., , 2004 . Fusion inhibitors like C-peptides also represent attractive candidate topical microbicides for the following reasons: (1) they inhibit an early stage in the HIV life cycle; (2) they are likely to work locally within tissue at nanomolar concentrations; and (3) they target a gp41 sequence that is highly conserved, decreasing the likelihood of rapid emergence of resistant virus (Root and Steger, 2004) . Here, using our skin explant system, we show that the potent C-peptide C34 can block both HIV infection of human LCs and LC-mediated transfer of virus to T cells, providing impetus for future studies that utilize C-peptides to block mucosal transmission of HIV.
RESULTS

Continuous presence of C34 dose dependently blocks HIV infection of human epidermal LCs
Following established procedures to assess anti-viral efficacy in the skin explant model (Kawamura et al., 2000 (Kawamura et al., , 2003 (Kawamura et al., , 2004 Ball et al., 2003; Sugaya et al., 2004) , we first preincubated blister roofs with different doses of C34 for 20 minutes and then added HIV for 2 hours. Skin explants were then washed free of both virus and drug and cultured for 3 days, enabling epidermal LCs to migrate into the culture wells. Productive HIV infection of LCs was assessed by flow cytometry gated on cells intracellularly stained for HIV p24. We previously showed that treatment with zidovudine (AZT), which should have no effect on capture or surface binding of HIV virions by LCs, diminished HIV p24 þ LCs in a dosedependent manner (Kawamura et al., 2003) . In addition, the number of HIV p24 þ LCs progressively increased over the first several days after HIV exposure, indicating ongoing active HIV replication within LCs (Kawamura et al., 2003) . Therefore, we concluded that all HIV p24 þ LCs in this study represented productively infected cells, rather than HIV that was captured or bound.
C34 only partially blocked productive HIV infection of LCs, even at micromolar concentrations (100-to 1,000-fold greater than the IC 50 (50% of the maximum possible inhibitory response) for viral infection measured in vitro (Figure 1a and b) . Likewise, C34 showed only partial activity when added during the 3-day culture period following the initial 2-hour exposure of the blister roof to HIV (Figure 1c and d) . In analogous virion washout experiments using cultured CEM or HeLa cells, a similar inability of C-peptides to block all HIV infection has been observed (M.J. Root, unpublished results) .
The results are consistent with the mechanism of C-peptide inhibition; as they target an intermediate state in the fusion process, C-peptides must be present at the time of HIV membrane fusion. The absence of C34 during the initial blister roof incubation enabled the HIV present during this time to infect without hindrance. Similarly, the absence of C34 during the 3-day incubation period permitted LCs to be infected by virions that were not washed away, perhaps because they were attached to the cellular glycocalyx (e.g., through lectin-glycan interactions) and had not yet interacted with CD4 and a chemokine receptor. Consistent with these postulates, C34 completely blocked LC infection in a dosedependent manner when present before, during, and after exposing LCs to HIV (Figure 1e and f). The numbers of LC migrating into the media during the 3-day culture period were not affected by C34, suggesting that C34 was not toxic to LCs at the dose range studied (1-1,000 nM).
Comparing the anti-HIV effects of C34, PSC-RANTES, and AZT
In order to compare blocking effects of drugs with different modes of action, we performed experiments using 1 mM C34, 100 nM of PSC-RANTES (a RANTES analogue that inhibits binding of HIV with its cellular co-receptor CCR5), and 100 mM of AZT (a reverse transcriptase inhibitor). Skin explants were incubated with one of these three drugs before and during exposure to virus (labeled ''pre/during''), following virus exposure during the 3-day culture period (labeled ''post''), or before, during, and after infection (labeled ''all''). As we have previously reported (Kawamura et al., 2003 (Kawamura et al., , 2004 , pre-incubation of LCs with PSC-RANTES completely blocked LC infection ( Figure 2 ). Protection from infection after pre-incubation with PSC-RANTES would be expected given its inhibitory mechanism, which involves rapid induction of prolonged intracellular sequestration of CCR5 (Pastore et al., 2003; Hartley et al., 2004) . Here, however, PSC-RANTES partially blocked HIV infection (up to 50%), even when LCs were exposed to drug following a 2-hour exposure to virus (i.e., during the ''post'' period) ( Figure 2 ). As the inhibitory effects of PSC-RANTES are presumably limited to the blocking of gp120 binding to CCR5, the observed partial inhibition suggests that HIV Env/CCR5 interaction for at least some of the infecting virions occurs during the 3-day culture period following viral washout. Newly formed virus emerging from initially infected LCs is probably the main viral source in this type of experiment. To support this claim, we previously showed that cells emigrating from HIV-exposed explant tissue demonstrate classic ultrastructural features of LC (e.g., Birbeck granules) and show clear evidence of virions budding from cell surfaces (Kawamura et al., 2003) . We also previously ruled out the possibility that captured virus was a source of infection following initial exposure, showing that (a) Epidermal sheets were pre-incubated with different doses of C34 for 20 minutes at 371C, exposed to HIV for 2 hours, washed three times to remove virus and drug, and cultured for 3 days. (c) Epidermal sheets were exposed to HIV for 2 hours, washed three times to remove virus, and cultured for 3 days with different doses of C34. (e) Epidermal sheets were pre-incubated with different doses of C34 for 20 minutes at 371C, exposed to HIV for 2 hours, washed three times to remove virus and drug, and cultured for 3 days with different doses of C34. treatment of crawl-out LCs with trypsin did not change p24 production in co-cultures containing LCs and T cells (Kawamura et al., 2000) . In addition, mannan, a C-type lectin inhibitor that would be expected to interfere with capture of HIV virions, showed no blocking effect in our system (Kawamura et al., 2003 and data not shown).
Pre-incubation of skin explants with AZT partially blocked HIV infection, whereas AZT completely blocked HIV infection of LCs when present during the 3-day culture period (Figure 2 ). Taken together, these results are consistent with the known mechanisms of action of each of these three drugs, with PSC-RANTES acting on the earliest step (Envreceptor interaction) in the HIV life cycle, C34 acting on a slightly later step (receptor-induced membrane fusion), and AZT acting on the latest step (inhibition of reverse transcriptase following viral RNA entry into the cytoplasm). Moreover, the ''post'' PSC-RANTES results and the ''pre/ during'' and ''post'' C34 results also reveal that about half of all HIV-infected LCs in our model system are infected during the 2-hour exposure to virus, and about half are infected during the subsequent 3-day culture period.
Comparing the ability of C34, PSC-RANTES, and AZT to block HIV DNA integration into LC chromosomal DNA In experiments shown in Figures 1 and 2 , we utilized anti-HIV p24 intracellular staining and flow cytometry to detect and quantify productive infection of LCs 3 days following exposure to HIV. Unlike protease inhibitors that block maturation of HIV particles into infectious virions, all three tested drugs block steps in the HIV life cycle before integration of viral cDNA into the host cell genome. In order to confirm that C34 does indeed block before viral cDNA integration, we measured HIV gag DNA (which should only be present following reverse transcription) in LCs via realtime PCR. Consistent with the flow cytometry results, C34 in the ''all'' incubation condition period completely blocked HIV gag DNA expression, whereas C34 in the ''pre/during'' or ''post'' incubation conditions only partially blocked HIV gag DNA expression (Figure 3a and b) . Consistent with their mechanisms of action, PSC-RANTES in the ''pre/during'' incubation condition and AZT in the ''all'' incubation condition completely blocked viral DNA integration into LCs (Figure 3a and b) . This second, more sensitive measure of HIV infection confirms that all three anti-viral drugs, with different modes of action, can successfully block HIV infection of LCs present within skin explants.
C34 blocks the ability of LCs to transmit HIV to co-cultured T cells
The intended consequence of blocking HIV infection of LCs in genital mucosa is to disrupt LC-mediated viral transmission to T cells, which likely occurs in submucosal epithelium and in draining lymph nodes. We previously showed that when HIV attachment to LCs was blocked by PSC-RANTES, viral transfer to T cells was also blocked (Kawamura et al., 2003 (Kawamura et al., , 2004 . We examined whether C34 and AZT, drugs with different modes of action when compared to PSC-RANTES, could also block LC-mediated viral transmission to T cells. T cells co-cultured with LC that had been treated with C34 (''all'' incubation), PSC-RANTES (''pre/during'' incubation), or AZT (''all'' incubation) expressed almost no intracellular HIV p24 protein (Figure 4 ). Culture supernatants from these experimental conditions were also negative for HIV p24 protein ( Table 1 ), implying that the treated LCs failed to transmit HIV to T cells. These results suggest that blocking HIV infection of LCs either at a viral attachment step, a viral fusion/entry step, or at a reverse transcription step is sufficient to prevent viral transfer to T cells in our model system. Although it is possible that small amounts of residual drug had anti-HIV effects in T cells in later days of our assays, the bulk of our findings support the idea that C-type lectinmediated capture of HIV is not a major pathway by which epidermal LCs transfer virus to T cells (Kawamura et al., 2003 (Kawamura et al., , 2004 .
DISCUSSION
The HIV pandemic has continued unabated for over 25 years with the vast majority of new infections occurring across genital mucosal tissue (Royce et al., 1997; UNAIDS, 2006) . In the absence of a prophylactic vaccine against HIV, health measures designed to limit the numbers of new cases of sexually transmitted HIV infection have included the use of topical microbicides, drugs, or compounds that can be applied to genital tissue before sexual intercourse and potentially block transmission of HIV (Lederman et al., 2006) . Most compounds that have been put forth as potential microbicides, including nonoxynol-9 (Van Damme et al., 2002), BufferGel (Patton et al., 2004) , cyanovirin (Tsai et al., 2004) , C31G (Mauck et al., 2004) , and cellulose acetate phthalate (Neurath et al., 2002) , work in a nonspecific virucidal manner when tested in the laboratory. Limitations . Alternatively, we and others have focused on candidate topical microbicides that target specific steps in the HIV infection life cycle. Our previous work with PSC-RANTES, a CCR5 inhibitor that blocks viral attachment to cell membranes, has shown the validity of such a targeted approach for candidate microbicides (Lederman et al., 2004) . In this study, we show that inhibitors of gp41-mediated viral membrane fusion might also be of potential use in the development of topical microbicides. C34, an HIV fusion inhibitor that disrupts the function of HIV gp41 in a manner similar to T-20 (enfuvirtide), inhibited HIV infection of epidermal LCs in a dose-dependent manner when skin explants exposed to HIV were continuously incubated with drug. At the highest dose tested (1 mM), C34 completely blocked LCs infection (Figure 1) , and we showed that the block occurred before reverse transcription of HIV (Figure 3) , as expected based upon the anti-viral mechanisms of these two drugs (Jiang et al., 1993; Chan et al., 1998; Malashkevich et al., 1998; Munoz-Barroso et al., 1999) . In addition, we showed that C34 also blocked the ability of HIVexposed LCs to transfer virus to co-cultured T cells (Figure 4 and Table 1 ). Interestingly, C34 was shown to block mucosal simian immunodeficiency virus infection in a rhesus macaque model of HIV transmission (Veazey et al., 2005) . Taken together, these findings support the further development of C34 as a candidate microbicide.
In our previous studies, we tested candidate microbicides only in the ''pre/during'' condition because our main goal was to test drugs that downmodulated or blocked cell-surface HIV receptors (e.g., CD4) and HIV co-receptors (e.g., CCR5) (Kawamura et al., 2000 (Kawamura et al., , 2003 (Kawamura et al., , 2004 . In this study, we expanded our test culture conditions to include incubation with drugs for 3 days following the 2-hour HIV exposure period and incubation with drugs before, during, and after the 2-hour HIV exposure period. Taken together, our results using drugs with different modes of action and in different culture conditions suggest the following: (1) completely blocking initial entry of HIV on the day of infection results in no detectable HIV-infected LCs 3 days later, as occurs in the PSC-RANTES ''pre/during'' condition; (2) partial blocking by C34 in the ''pre/during'' and the ''post'' conditions suggests that a subset of virions that bind to CD4/CCR5 during the 2-hour infection period is blocked from fusing with cell membranes, but that another subset is subsequently free to fuse with cells and infect them after drug is washed out of the system; (3) partial blocking by PSC-RANTES in the ''post'' condition suggests that roughly half of all HIV-infected LCs detected on day 3 are infected during the 2-hour infection period and that roughly half are infected during the 3-day culture period; and (4) although not able to prevent virus binding and viral entry, AZT, if continually present in LC cultures, blocks active HIV replication in these cells.
It is now clear from numerous in vitro studies that there are at least two pathways by which HIV interacts with dendritic cell: (1) CD4-and CCR5-mediated infection by virus and (2) cell-surface capture of virus by dendritic cell-SIGN and other C-type lectins (Geijtenbeek et al., 2000; Turville et al., 2001 Turville et al., , 2002 . Langerin is a C-type lectin specific to LC that has been shown to bind HIV gp120 and mediate capture when LCs are in cell suspension (Turville et al., 2002) . It is still unclear, however, whether dendritic cell in situ, especially LCs embedded within epithelial cell layers, can capture HIV via C-type lectins. Genetic studies have shown that individuals with homozygous deletions in the open reading frame of CCR5 are largely protected from initial HIV infection despite numerous exposures (Dean et al., 1996; Huang et al., 1996; Liu et al., 1996; Samson et al., 1996) . These observations suggest the importance of CCR5, and not C-type lectins, as a critical cofactor involved in sexual transmission of HIV. Using our skin tissue explant model, we have found no evidence that C-type lectins expressed by LCs within epithelium are involved in transmission of virus from LCs to CD4 þ T cells, both in previously published work (Kawamura et al., 2003 (Kawamura et al., , 2004 and in this study ( Figure 4 and Table 1 ). Instead, our findings suggest that LC-mediated transmission of virus to T cells ex vivo requires LC infection in a CD4-and CCR5-dependent manner.
Blocking HIV infection of LCs at mucosal surfaces through topical application of a microbicide appears to be valid approach. In a proof of concept study, PSC-RANTES, when applied intravaginally 15 minutes before intravaginal simian immunodeficiency virus exposure, completely blocked infection of rhesus macaques (Lederman et al., 2004) . Targeting of other early steps in the HIV life cycle, as emphasized here, may also prove effective (Veazey et al., 2005) . Lastly, combination approaches using drugs with different modes of action may provide protection in a clinically meaningful manner, either through synergistic or additive effects, or simply by reducing the amounts and costs of drugs needed to provide complete protection.
MATERIALS AND METHODS
Healthy skin and blood donors
In accordance with the Declaration of Helsinki Principles, the Institutional Review Board of the National Cancer Institute approved all aspects of this study, and informed consent was obtained from all healthy individuals volunteering for the suction blister ) were collected 3 days after HIV exposure, washed three times, co-cultured with 1 Â 10 6 allogeneic CD4 þ T cells for 7 days, stained with anti-HIV p24 and anti-CD3 mAbs, and examined by flow cytometry. For C34 (1 mM) and AZT (100 mM), drugs were continuously present (''all'' conditions), whereas for PSC-RANTES (100 nM), drug was present only before and during exposure to HIV (''pre/during'' condition). Representative dot plots from one of three separate experiments are shown. 
Reagents
Phycoerythrin-conjugated mouse anti-human HLA-DR mAb (clone: G46-6) and phycoerythrin-conjugated mouse anti-human CD3 mAb (clone: UCHT1) were purchased from Pharmingen (San Diego, CA). FITC-conjugated rat anti-p24 mAb was purchased from Beckman-Coulter (Fullerton, CA). PSC-RANTES and C34 were synthesized and purified as described previously (Chan et al., 1997; Hartley et al., 2004) . AZT was purchased from Sigma Chemical Co. (St Louis, MO). Purified, pelleted, and titered HIV BaÀL (stock at 10 7.67 TCID 50 /ml) was purchased from Advanced Biotechnologies Inc. (Columbia, MD).
Inhibition of HIV infection in LCs ex vivo
Epithelial tissue explants were prepared from suction blister roofs of healthy volunteers and LCs within these explants were infected as described previously (Kawamura et al., 2000 (Kawamura et al., , 2003 (Kawamura et al., , 2004 Sugaya et al., 2004) . Briefly, 100 ml droplets containing HIV BaÀL at a 1:50 dilution were placed on the inside surface of sterile plastic culture dish covers and explants were draped over droplets and incubated together at 371C for 2 hours. For some experiments, 50 ml droplets containing AZT (200 mM), PSC-RANTES (200 nM), or C34 (0.2 nM to 2 mM) were placed on the inside surface of sterile plastic culture dish covers. Explants were draped over droplets for 20 minutes at 371C; 50 ml of HIV BaÀL at 1:50 final dilution was then added to reagents under the explants and incubated for 2 additional hours at 371C. Explants were washed three times with sterile phosphate-buffered saline, and then floated in six-well plates containing 4 ml of complete medium. For some experiments, culture medium containing AZT (100 mM), PSC-RANTES (100 nM), or C34 (0.1 nM to 1 mM) was used.
Assessment of HIV transmission to CD4 þ T cells
Allogeneic peripheral blood mononuclear cells were collected from venous blood and were enriched for CD4 þ T cells by negative selection using a commercially prepared mAb mixture/complement reagent (Lympho-Kwik; One Lambda, Los Angeles, CA; 490% pure as assessed by flow cytometry). LCs (1 Â 10 4 ) that crawled out from epidermal sheets which had been treated with C34 (pre/ during/post HIV exposure), PSC-RANTES (pre/during HIV exposure), or AZT (pre/during/post HIV exposure) were thoroughly washed to minimize transfer of residual non-cell-associated virus or drugs and then co-cultured with 1 Â 10 6 allogeneic T cells in 24-well plates for 7 days.
Assessment of LC and LC-T-cell infection by HIV
HIV infections of LC and LC-T-cell populations were assessed by flow cytometry for intracellular HIV p24 protein and by ELISA for HIV p24 protein levels in co-culture supernatants (Kawamura et al., 2000 (Kawamura et al., , 2003 (Kawamura et al., , 2004 . LC that had emigrated from tissue into media 3 days following HIV exposure of explants or LC-T-cell populations co-cultured for 7 days were collected, passed through a 70-mM mesh, washed three times in 2% human AB serum/phosphate-buffered saline (staining buffer), pre-incubated in staining buffer for 10 minutes at room temperature to block nonspecific staining, and then incubated with phycoerythrin-conjugated mouse anti-human HLA-DR mAb or phycoerythrin-conjugated mouse anti-human CD3 mAb for 30 minutes at 41C. Cells were then washed three times in staining buffer, incubated with Dead Red (Molecular Probes, Eugene, OR) for 20 minutes at room temperature to label dead cells, washed three times in staining buffer, and fixed and permeabilized with cytofix/cytoperm reagents (Pharmingen) for 20 minutes at 41C. Cells were then washed three times in PermWash (Pharmingen), incubated with 10 mg/ml FITC-conjugated rat anti-p24 mAb diluted in Perm/Wash for 30 minutes at 41C and examined by flow cytometry using a FACScan s (Becton Dickinson, Mountain View, CA) equipped with Lysis TM II software (Becton Dickinson). Dead cells, that is, Dead Red-positive cells, were excluded from all analyses. The percentages of HIV-infected LCs or T cells reported here were always calculated by first subtracting any background values obtained when cells that had not been exposed to HIV were stained.
For detection of secreted HIV p24 protein, supernatants were harvested on days 5 and 7 from co-cultures of emigrated LCs and CD4 þ T cells, inactivated with 2% (v/v) Triton X-100 (Sigma) in phosphate-buffered saline, and frozen at À201C. After collecting supernatants, samples were thawed and examined for HIV p24 protein content by ELISA (Beckman Coulter, Miami, FL).
Quantitative real-time PCR for HIV gag DNA
The numbers of LC that had emigrated from tissue into media for 3 days were counted and DNA were purified using DNeasy Tissue kit (Qiagen Inc., Valencia, CA). The total volume of DNA extracted from LCs with the kit was 200 ml. Quantitative real-time PCR was then performed in a total volume of 50 ml, including 25 ml of SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA), 1 ml of each primer (final 500 nM), and 20 ml of DNA. Thermal amplification was performed using the following linked profile: 10 minutes at 951C, 40 cycles of denaturation (951C for 15 seconds), and annealing/extension (601C for 1 minutes) in a 7700 sequence detection system (Applied Biosystems). Primer sequences used to detect HIV gag DNA were SK38 and SK39 from GeneAmplimer s HIV Control reagents (Applied Biosystems). Positive control DNA of the HIV genome was used for the standards and HIV gag copies per 10 5 cells were calculated.
Statistical analysis
Statistical analyses were performed using the Kruskal-Wallis test.
